Compositions for regenerating defective or absent myocardium
US-9199001-B2 · Dec 1, 2015 · US
Dominant-negative FGF2 antagonists
US11229681B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11229681-B2 |
| Application number | US-201816033007-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 11, 2018 |
| Priority date | Jul 14, 2017 |
| Publication date | Jan 25, 2022 |
| Grant date | Jan 25, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides dominant negative mutants of FGF2 for suppressing FGF-mediated cellular signaling. Related compositions, methods, and kits are disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising: (1) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, wherein the amino acid sequence of SEQ ID NO:1 has (A) an E substitution at K119 and an E substitution at R120 or (B) an E substitution at K125, and wherein the polypeptide suppresses FGF2 signaling; (2) an anti-angiogenic agent; and (3) a physiologically acceptable carrier. 2. The composition of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1, and wherein the amino acid sequence of SEQ ID NO:1 has (A) an E substitution at K119 and an E substitution at R120 or (B) an E substitution at K125. 3. The composition of claim 2 , wherein the amino acid sequence of SEQ ID NO:1 has an E substitution at K125. 4. The composition of claim 2 , wherein the amino acid sequence of SEQ ID NO:1 has an E substitution at K119 and an E substitution at R120. 5. The composition of claim 1 , wherein the amino acid sequence of SEQ ID NO:1 has an E substitution at K119 and an E substitution at R120. 6. The composition of claim 1 , wherein the amino acid sequence of SEQ ID NO:1 has an E substitution at K125. 7. The composition of claim 1 , wherein the polypeptide further comprises at least one heterologous amino acid sequence at the N- and/or C-terminus of the amino acid sequence of SEQ ID NO: 1. 8. A method for suppressing FGF2 signaling in a mammal, comprising administering to the mammal an effective amount of the composition of claim 1 . 9. The method of claim 8 , wherein the composition is administered orally. 10. The method of claim 8 , wherein the composition is administered topically. 11. The method of claim 8 , wherein the composition is administered intravenously. 12. The method of claim 8 , wherein the mammal has a vascularized solid tumor or metastases from a primary tumor. 13. The method of claim 8 , wherein the mammal is a human. 14. A kit for suppressing FGF signaling, comprising (1) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, wherein the amino acid sequence of SEQ ID NO:1 has (A) an E substitution at K119 and an E substitution at R120 or (B) an E substitution at K125, and wherein the polypeptide suppresses FGF2 signaling; and (2) an anti-angiogenic agent. 15. The kit of claim 14 , further comprising an instruction manual.
Assignees
Inventors
Classifications
- A61K38/1825Primary
Fibroblast growth factor [FGF] · CPC title
acidic FGF [aFGF] · CPC title
Antineoplastic agents · CPC title
Fusion polypeptide · CPC title
basic FGF [bFGF] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11229681B2 cover?
- The present invention provides dominant negative mutants of FGF2 for suppressing FGF-mediated cellular signaling. Related compositions, methods, and kits are disclosed.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1825. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).